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MODERATE-severe depression (MSD) is linked to over-
expression of proinflammatory cytokines and che-
mokines. Fractalkine (FKN) and macrophage
inflammatory protein-1 alpha (MIP-1a) are, respec-
tively, members of CX3C and C
/C chemokines, and
both are involved in recruiting and activating mono-
nuclear phagocytes in the central nervous system. We
analysed the presence of FKN and MIP-1a in sera of
untreated MSD patients and healthy donors. High
FKN levels were observed in all MSD patients as
compared with values only detectable in 26% of
healthy donors. MIP-1a was measurable in 20% of
patients, while no healthy donors showed detectable
chemokine levels. In conclusion, we describe a
previously unknown involvement of FKN in the
pathogenesis of MSD, suggesting that FKN may
represent a target for a specific immune therapy of
this disease.
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Depression represents a major public health pro-
blem. The interactions between the central nervous
system (CNS) and the immune system in depression
have a biological explanation supported by the
monoamine hypothesis, deregulation of
hypothalamic/pituitary/adrenocortical activity, and
the macrophage theory, which proposes that an
excessive secretion of macrophage cytokines such
as interleukin-1 may provoke the hormonal abnorm-
alities linked to depression.
1
In the superfamily of cytokines, the chemo-
kines appear as a rapidly evolving family of inter-
cellular mediators, with their number and variety
growing. These key factors in the immune response
have been associated with the trafficking of leuko-
cytes in physiological immune surveillance as well as
with inflammatory cell recruitment in different dis-
eases.
2
In the CNS, chemokine signalling plays an impor-
tant role in neuropathological processes, in addition
to the relevant role played under physiological
processes, such as neuronal migration and modula-
tion of synaptic transmission, conditions.
2
The CX3C or d-chemokines include only one
member, called CX3CL1/fractalkine (FKN), in which
the first two cysteines are separated by three amino
acids. This molecule exists in both membrane-
anchored and soluble isoforms.
2
FKN is highly expressed in the CNS, being loca-
lized on neuronal cells, while its receptor, CX3CR1, is
exclusively found on microglia and astrocytes.
2
The finding of a constitutive and abundant neuro-
nal mRNA expression for FKN favours the view of
more physiological functions of FKN such as the
mediation of adhesion and cell/cell communication
between FKN-producing neurones and microglia that
express FKN receptor. This cellular cross-talk may
also occur in the total absence of pro-inflammatory
conditions.
2
The CC or b-chemokines contain four conserved
cysteines, the first two of which are adjacent. Macro-
phage inflammatory protein-1 alpha (MIP-1a),
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205a member of C/Co rb-chemokines, has been
implicated in the pathogenesis of several human
diseases with inflammatory components.
2 MIP-1a
plays a key role in recruiting and activating mono-
nuclear phagocytes in the CNS, microglia and astro-
cytes being sources of this chemokine.
2
Suarez et al. have reported that men with mild to
moderate levels of depressive symptoms showed
overexpression of monocyte-associated proinflam-
matory cytokines and chemokines.
3
In line with these findings, since no data on a
possible association of FKN and MIP-1a release and
depression disease are currently available, we inves-
tigated FKN and MIP-1a serum levels in patients
affected by moderate-severe depression (MSD), be-
fore any anti-depression therapy.
In this study, we enrolled nine female patients
with MSD (mean age, 36.49 /12.1 years) who experi-
enced a major depressive episode according to
DSM-IV criteria, recruited from the Outpatient
Mental Health Service of the Department of Neuros-
ciences, Psychiatry and Anesthesiology. Mood was
assessed at baseline using the Beck Depression
Inventory (range, 0/63). The mean baseline
score of the Beck Depression Inventory was 30.2.
Fifteen healthy females (mean age, 34.79 /11.3
years) were also enrolled as controls. Patients and
healthy donors (HD) signed an informed consent
form.
Sera were obtained from peripheral blood allowed
to clot at room temperature for 2 h, separated by
centrifugation at 200 /g for 15 min in a 4235 A
centrifuge (ALC Int. S.r.L., Milan, Italy), and stored at
 /808C until use.
Soluble FKN was measured in an enzyme-linked
immunosorbent assay, using DUOSET from R&D
System Inc. (SPACE Import/Export, Milan, Italy).
The sensitivity of 156 pg/ml was obtained by gentle
plate agitation during all incubation steps.
Serum MIP-1a levels were determined by an
immunoenzymatic method (Quantikine Human
MIP-1a; R&D System Inc., SPACE Import/Export).
The minimum detectable dose of MIP-1a is typically
less than 10 pg/ml.
Data are expressed as the mean9 /standard devia-
tion. pB /0.05 was considered significant.
We found high levels of FKN in all nine MSD
patients (1078.29 /302.3 pg/ml) (Table 1) and in only
4/15 (26%) HD at lower concentrations (212.59 /63.5
pg/ml). Detectable levels of MIP-1a were found in
2/9 (22%) MSD patients (56 and 72 pg/ml, respec-
tively) (Table 1) and no detectable levels in HD sera.
There is clinical and experimental evidence of
severe alterations of the immune and endocrine
systems linked to depression. In particular, it has
been shown that the activation of the brain chemo-
kine system is associated with depression, although
the exact relationship between sickness behaviour
and depression is still elusive.
3
The results of this preliminary study, which is the
first investigating the relationship between FKN and
MIP-1a with MSD, show high FKN serum levels in all
patients and detectable values of FKN in 4/15 (26%)
HD only, and detectable levels of MIP-1a in only 20%
patients and no detectable levels in HD sera.
Thus, we can hypothesize an involvement of FKN
release in the pathogenesis of MSD disease.
As previously reported by other investigators, our
data support the demonstration that MSD disease is
characterized by an increased immune response
activity and that the systemic immune stimulation
participates in the pathogenesis of this disease.
In a previous study, we demonstrated that inter-
leukin-18, which promotes T helper (Th) 1 re-
sponses, is elevated in patients affected by MSD,
whereas sCD30, expressed by activated Th2, is
undetectable in the same patients.
4 In this respect,
it has been shown that chemokines are an important
component of polarized type I and type II
responses.
5
Fraticelli et al. demonstrated that CX3CR1 is
strongly expressed in natural killer cells and, at lower
levels, in polarized Th1 cells, which respond chemo-
tactically to FKN, unlike Th2 populations, contrary to
other chemokines such as MIP-1a (CCR1 agonist) that
possess a comparable activity for Th1 and Th2 cells.
These data suggest that FKN and its cognate receptor
CX3CR1 are part of the chemokine-based amplifica-
tion and orientation circuits of polarized Th1
responses.
5
Therefore, our study strengthens the hypothesis
that MDS disease is associated with an activation of
cellular immunity and an induction of inflammatory
response, mainly Th1 type mediated, at least in part,
by FKN. Further studies are needed to clarify the
relationship between the pathophysiology of MDS
and elevated FKN levels.
In conclusion, our preliminary findings provide
new insight into the immunopathogenesis of MDS,
and suggest that FKN may represent a target for a
specific immune therapy for this disease.
Table 1. Serum levels of FKN and MIP-1a in patients affected
by MSD
Patient number FKN (pg/ml) MIP-1a (pg/ml)
1 813 Not detected
2 1262 Not detected
3 554 72
4 1124 56
5 1179 Not detected
6 1201 Not detected
7 781 Not detected
8 1529 Not detected
9 1261 Not detected
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